Skip to main content
. Author manuscript; available in PMC: 2014 Mar 1.
Published in final edited form as: J Pharm Sci. 2012 Dec 4;102(3):892–903. doi: 10.1002/jps.23387

Table 3.

Transport Lag Times of Permeants*

Lag Time (h)
Bevacizumab 24 ± 13
Ranibizumab 10 ± 2
FITC-BSA 9.2 ± 6.2
FITC-ficoll 70 kDa 5.0 ± 3.8
FITC-dextran 20 kDa 2.7 ± 1.0
FITC-dextran 40 kDa 2.7 ± 1.0
FITC-dextran 150 kDa 4.4 ± 2.8
*

Data represent the mean and standard deviation of at least three sclera samples for each permeant.